Cleveland Clinic's Center for Personalized Healthcare: setting the stage for value-based care
PHARMACOGENOMICS
Authors: Teng, Kathryn; DiPiero, Jennifer; Meese, Thad; Doerr, Megan; Leonard, Mandy; Daly, Thomas; Lacbawan, Felicitas; Chalmers, Jeff; Stowe, David; Knoer, Scott; Hicks, J. Kevin
Abstract
Cleveland Clinic (OH, USA) launched the Center for Personalized Healthcare in 2011 to establish an evidence-based system for individualizing care by incorporating unique patient characteristics, including but not limited to genetic and family health history information, into the standard medical decision-making process. Using MyFamily, a web-based tool integrated into our electronic health record, a patient's family health history is used as a surrogate for genetic, environmental and behavioral risks to identify those with an elevated probability of developing disease. Complementing MyFamily, the Personalized Medication Program was created for the purpose of identifying gene-drug pairs for integration into clinical practice and developing the implementation tools needed to incorporate pharmacogenomics into the clinical workflow. We have successfully implemented the gene-drug pairs HLA-B*57:01-abacavir and TPMT-thiopurines into patient care. Our efforts to establish personalized medical care at Cleveland Clinic may serve as a model for large-scale integration of personalized healthcare.
Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Authors: Ebbesen, Maria S.; Nygaard, Ulrikka; Rosthoj, Susanne; Sorensen, Ditte; Nersting, Jacob; Vettenranta, Kim; Wesenberg, Finn; Kristinsson, Jon; Harila-Saari, Arja; Schmiegelow, Kjeld
Abstract
Hepatotoxicity is a known toxicity to treatment of childhood acute lymphoblastic leukemia. Hepatotoxicity occurs during maintenance therapy and is caused by metabolites of 6-Mercaptopurine (6 MP) and Methotrexate (MTX). Our objective was to investigate the association between alanine aminotransferases (ALAT) levels and relapse rate. We included 385 patients enrolled in the NOPHO ALL-92 protocol. Data on ALAT levels, 6 MP and MTX doses, cytotoxic MTX/6 MP metabolites, and thiopurine methyltransferase (TPMT) activity were prospectively registered. In total, 91% of the patients had a mean ALAT (mALAT) level above upper normal limit (40 IU/L) and ALAT levels were positively correlated to 6 MP doses (r(s) = 0.31; P < 0.001). In total, 47 patients suffered a relapse, no difference in mALAT levels were found in these compared with nonrelapse patients (median, 107 vs. 98 IU/L; P = 0.39). mALAT levels in patients classified as TPMT high activity (TPMTWT) were higher than in TPMT low-activity patients (median, 103 vs. 82 IU/L; P = 0.03). In a Cox regression model risk of relapse was not associated with ALAT levels (P = 0.56). ALAT levels increased 2.7%/month during the last year of maintenance therapy (P < 0.001). In conclusion, elevated ALAT levels are associated with TPMTWT and may indicate treatment adherence in these patients. If liver function is normal, elevated ALAT levels should not indicate treatment adaptation.